The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1737
ISSUE1737
September 15, 2025
Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction
September 15, 2025 (Issue: 1737)
Inclisiran (Leqvio – Novartis), a subcutaneously
injected small interfering RNA (siRNA) that decreases
LDL-cholesterol (LDL-C) levels by reducing synthesis
of proprotein convertase subtilisin/kexin type 9
(PCSK9), has been approved by the FDA...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.